Michael Patrick Savage

20110028469, Feb 3, 2011

Sep 24, 2008

12/680763

Eric C. Anderson - Houston TX, US
Brian Dupre - Houston TX, US
Robert V. Market - Houston TX, US
Keith A. Monk - Houston TX, US
Michael M. Savage - Houston TX, US

A61K 31/5377
C07D 413/12
C07D 409/12
A61K 31/4025
A61P 35/00
A61P 35/02
A61P 31/18
A61P 3/00
A61P 29/00

5142315, 544146, 548527, 514422

Provided are compounds of Formula (I) or of Formula (II) that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or amelioratin diseases associated with modulation of CCR9 receptor activity.

20130236434, Sep 12, 2013

Nov 16, 2011

13/885537

Ronald J. Biediger - Houston TX, US
Robert V. Market - Houston TX, US
Michael M. Savage - Houston TX, US
Peter Vanderslice - Houston TX, US

TEXAS HEART INSTITUTE - Houston TX

A61K 47/48
C07D 317/60
C07D 275/02
C07D 213/64
C07D 409/14
C07C 271/20
C07D 333/20
C07C 311/08

424 937, 549 59, 549 75, 514444, 514438, 549441, 514466, 544146, 5142315, 564 99, 514605, 546300, 514351, 549 74, 549 60, 435375, 560158, 514483, 548214, 514372

A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

20200001367, Jan 2, 2020

Jun 27, 2018

16/020519

- Houston TX, US
Michael T. Savage - Magnolia TX, US
James Andy Oxford - Magnolia TX, US

B22F 5/00
B28B 1/00
B22F 7/06
B33Y 70/00
B22D 19/06

In some embodiments, the present disclosure includes a method of forming a body of an earth-boring downhole tool. A mold is formed that has at least one interior surface defining a mold cavity within the mold. The mold cavity has a shape corresponding to a shape of the body of the earth-boring downhole tool to be formed therein. At least one insert is formed that includes particles of hard-phase material and a binder material using an additive manufacturing process. The at least one insert is positioned within the mold cavity. Additional particles of hard-phase material are provided within the mold cavity, and the additional particles of hard-phase material are infiltrated with molten metal, thus sintering and/or infiltrating the at least one insert to form the body of the earth-boring downhole tool. The resulting body of the earth-boring downhole tool includes the sintered and/or infiltrated at least one insert.

20190225602, Jul 25, 2019

Apr 1, 2019

16/372189

Ronald J. Biediger - Houston TX, US
Michele A. Benish - The Woodlands TX, US
Robert V. Market - Pearland TX, US
Michael M. Savage - Pearland TX, US
Brandon M. Young - Germantown TN, US

Aviara Pharmaceuticals, Inc. - Houston TX

C07D 417/12
C07D 213/75
C07D 409/12

Provided herein are methods for antagonizing the action of an α4-integrin to treat various pathophysiological conditions utilizing pharmaceutical compositions of compounds or pharmaceutically acceptable salts or stereoisomer(s) thereof of formula Iwhere R, R, R, R, R, X and Rare as described herein.

20190210992, Jul 11, 2019

Mar 14, 2019

16/354011

- Houston TX, US
Robert V. MARKET - Houston TX, US
Michael M. SAVAGE - Houston TX, US

TEXAS HEART INSTITUTE - Houston TX

C07D 333/20
C07D 409/14
C07D 275/02
C07D 409/12
C07D 333/10
A61K 35/51
A61K 35/17
C07D 333/24
A61K 35/12
C07C 229/34
C07C 271/22
C07D 317/60
C07D 213/64
C07C 311/08
C07C 271/20
C07D 413/14

A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4fβ1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

20180371843, Dec 27, 2018

Jun 26, 2017

15/633530

- Houston TX, US
Michael T. Savage - Magnolia TX, US

E21B 10/54
B23K 1/00

Earth-boring tools may include a body having blades protruding therefrom and at least one hardfacing pad secured to at least one blade. The at least one hardfacing pad may be located at least partially within a recess extending at least into the at least one blade body around a circumference of a gage region of the body and may include a plate, an abrasion-resistant material secured to the plate on a side of the plate opposite the body, and at least one spacer extending from the plate toward the body, such that the plate is spaced from the body by at least a thickness of the at least one spacer. A braze material may secure the at least one hardfacing pad to the at least one blade, the braze material extending around the at least one spacer and located between the plate and the body.

20180312498, Nov 1, 2018

Apr 26, 2017

15/497416

Ronald J. Biediger - Houston TX, US
Michele A. Benish - The Woodlands TX, US
Robert V. Market - Pearland TX, US
Michael M. Savage - Pearland TX, US
Brandon M. Young - Germantown TN, US

Aviara Pharmaceuticals, Inc. - Houston TX

C07D 417/12
C07D 213/75

Provided herein are compounds and pharmaceutical compositions of formula Iwhere R, R, R, R, R, X and Rare as described herein. Also provided pharmaceutically acceptable salts or stereoisomer(s) of these compounds. In addition methods are provided for antagonizing the action of an α4-integrin to treat various pathophysiological conditions.

20170044130, Feb 16, 2017

Oct 26, 2016

15/334890

- Houston TX, US
Robert V. MARKET - Houston TX, US
Michael M. SAVAGE - Houston TX, US
Peter VANDERSLICE - Houston TX, US

C07D 333/20
C07C 311/08
C07D 275/02
C07C 271/20
C07D 409/14
C07D 317/60
C07D 213/64

A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.